Keywords:
Neuroradiology brain, MR, MR-Spectroscopy, MR-Diffusion/Perfusion, Diagnostic procedure, Intensity Modulated Radiotherapy (IMRT), Treatment effects, Outcomes, Cancer, Multidisciplinary cancer care
Authors:
N. Dichko1, Y. Kmetyuk2, K. A. Musaieva2, O. Silaieva2; 1Kyiv/UA, 2Kiev/UA
DOI:
10.26044/ecr2019/C-2196
Aims and objectives
The critical biological characteristic of a Glioblastoma (GBM) is an inevitable progression after standard therapy with survival less than one year (mean 6,9 months) from the time of diagnosis.
Tumor recurrence develops in almost all patients despite the aggressive standard first line treatment with radiotherapy and concomitant or adjuvant temozolomide (RT + TMZ).
Thus,
prediction of poor treatment response (early relapse) to the standard first line treatment of GBM is of high clinical significance,
especially in the view of new emerging salvage treatment options such as re-irradiation,
bevacizumab,
irinotecan etc.
Multiparametric MRI utilizes advanced imaging methods,
such as diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping,
and the proton MR spectroscopy (MRS),
it allows much deeper and still non-invasive insight into the interpretation of brain lesions,
resulting in greater specificity of diagnostic imaging.
The aim of this retrospective single-institutional study is to determine prognostic utility of the main metabolite concentrations obtained by MRS and the values of ADC at baseline diagnostic MRI study in stratification patients for early and late tumour recurrence.